BioMarin and n‑Lorem Foundation entered an early research collaboration to develop an investigational antisense oligonucleotide for ReNU syndrome. The partnership targets a disease with no approved therapy and leverages BioMarin’s genetic‑medicines leadership, potentially creating a new revenue stream and advancing ASO‑based rare‑disease treatment. Who is involved: BioMarin, n‑Lorem Foundation, and the ReNU syndrome patient community.. Likely next: Preclinical studies will commence, with an IND filing anticipated if proof‑of‑concept data are generated, followed by potential clinical trials.. On July 27 2026, BioMarin and the n‑Lorem Foundation announced an early‑stage research collaboration to develop an investigational antisense oligonucleotide (ASO) aimed at the genetic root of ReNU syndrome, a disease first identified in 2024 with no approved treatments. The deal pairs BioMarin’s established genetic‑medicines platform with n‑Lorem’s expertise in designing custom ASOs for ultra‑rare disorders. While no financial terms or timelines were disclosed, the collaboration signals BioMarin’s continued investment in expanding its rare‑disease pipeline beyond existing approvals such as Voxzogo. Success could yield a first‑in‑class medicine and reinforce the company’s position in the ASO therapeutic space. Sectors affected: rare disease genetic medicines antisense oligonucleotide therapeutics Historical parallels: FDA acceptance of BioMarin’s supplemental NDA for Voxzogo (vosoritide) for achondroplasia – July 13 2026
INTELLIGENCE
Social Pulse
AI estimate · not scraped